{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:47:20Z","timestamp":1793713640128,"version":"4.6.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01003-x","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:02:55Z","timestamp":1730350975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-5143","authenticated-orcid":false,"given":"Chun K.","family":"Chew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Bavanandan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norliza","family":"Zainudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeyya","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damenthi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosnawati","family":"Yahya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen S.","family":"Ch\u2019ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai H.","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azrini","family":"Abdul Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Rajasuriar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9733-1126","authenticated-orcid":false,"given":"Geok Y.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9814-1431","authenticated-orcid":false,"given":"Aisyah","family":"Mohd Norzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6397-5735","authenticated-orcid":false,"given":"Kit Y.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan H.","family":"Wan Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad R.","family":"Mohd Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan M. R.","family":"Wan Ahmad Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-6421","authenticated-orcid":false,"given":"Min H.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4242-7690","authenticated-orcid":false,"given":"Yusi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon K.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5413-0324","authenticated-orcid":false,"given":"Jau S.","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck O.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon S. M.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"key":"1003_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1003_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"SA Halperin","year":"2022","unstructured":"Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 399, 237\u2013248 (2022).","journal-title":"Lancet"},{"key":"1003_CR3","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N. Engl. J. Med. 385, 2348\u20132360 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1003_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA 326, 35\u201345 (2021).","journal-title":"JAMA"},{"key":"1003_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/S1473-3099(22)00422-4","volume":"22","author":"P Arora","year":"2022","unstructured":"Arora, P. et al. Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5. Lancet Infect. Dis. 22, 1117 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1003_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 399, 924\u2013944 (2022).","journal-title":"Lancet"},{"key":"1003_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J. & Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 28, 202\u2013221 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"1003_CR8","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nat. 608, 593\u2013602 (2022).","journal-title":"Nat."},{"key":"1003_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bsheal.2022.01.002","volume":"4","author":"Z Xu","year":"2022","unstructured":"Xu, Z., Liu, K. & Gao, G. F. Omicron variant of SARS-CoV-2 imposes a new challenge for the global public health. Biosaf. Heal. 4, 147\u2013149 (2022).","journal-title":"Biosaf. Heal."},{"key":"1003_CR10","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.immuni.2022.06.005","volume":"55","author":"M Huang","year":"2022","unstructured":"Huang, M. et al. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1\/BA.1.1\/BA.2\/BA.3. Immunity 55, 1501\u20131514.e3 (2022).","journal-title":"Immunity"},{"key":"1003_CR11","first-page":"916","volume":"328","author":"HD Larkin","year":"2022","unstructured":"Larkin, H. D. New Data on Heterologous COVID-19 Vaccine Combinations. JAMA 328, 916\u2013917 (2022).","journal-title":"JAMA"},{"key":"1003_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1001\/jama.2022.1922","volume":"327","author":"SHX Tan","year":"2022","unstructured":"Tan, S. H. X. et al. Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore. JAMA 327, 1181\u20131182 (2022).","journal-title":"JAMA"},{"key":"1003_CR13","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4014\/jmb.2111.11026","volume":"31","author":"SulS Mattoo","year":"2021","unstructured":"Mattoo, SulS. & Myoung, J. A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. J. Microbiol. Biotechnol. 31, 601\u20131614 (2021).","journal-title":"J. Microbiol. Biotechnol."},{"key":"1003_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521\u2013529 (2022).","journal-title":"Lancet"},{"key":"1003_CR15","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMc2119426","volume":"386","author":"X Zhao","year":"2022","unstructured":"Zhao, X. et al. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant. N. Engl. J. Med. 386, 894\u2013896 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1003_CR16","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e14 (2022).","journal-title":"Cell"},{"key":"1003_CR17","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2022.0470","volume":"327","author":"EK Accorsi","year":"2022","unstructured":"Accorsi, E. K. et al. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA 327, 639\u2013651 (2022).","journal-title":"JAMA"},{"key":"1003_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMc2200133","volume":"386","author":"HN Altarawneh","year":"2022","unstructured":"Altarawneh, H. N. et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N. Engl. J. Med. 386, 1288\u20131290 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1003_CR19","doi-asserted-by":"publisher","first-page":"101334","DOI":"10.1016\/j.coviro.2023.101334","volume":"61","author":"S Afkhami","year":"2023","unstructured":"Afkhami, S., Kang, A., Jeyanathan, V., Xing, Z. & Jeyanathan, M. Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19. Curr. Opin. Virol. 61, 101334 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"1003_CR20","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14712598.2022.2156284","volume":"23","author":"I Garc\u00eda-Silva","year":"2023","unstructured":"Garc\u00eda-Silva, I., Govea-Alonso, D. O. & Rosales-Mendoza, S. Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity. Expert. Opin. Biol. Ther. 23, 207\u2013222 (2023).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"1003_CR21","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.immuni.2022.10.017","volume":"55","author":"I Wahl","year":"2022","unstructured":"Wahl, I. & Wardemann, H. Sterilizing immunity: Understanding COVID-19. Immunity 55, 2231 (2022).","journal-title":"Immunity"},{"key":"1003_CR22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S2213-2600(22)00407-6","volume":"11","author":"M Yechezkel","year":"2023","unstructured":"Yechezkel, M. et al. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study. Lancet Respir. Med. 11, 139\u2013150 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1003_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S2213-2600(23)00049-8","volume":"11","author":"R Tang","year":"2023","unstructured":"Tang, R. et al. Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial. Lancet Respir. Med. 11, 613\u2013623 (2023).","journal-title":"Lancet Respir. Med."},{"key":"1003_CR24","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1056\/NEJMc2202542","volume":"386","author":"G Regev-Yochay","year":"2022","unstructured":"Regev-Yochay, G. et al. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron. N. Engl. J. Med. 386, 1377\u20131380 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1003_CR25","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/14760584.2021.1903878","volume":"21","author":"R Heida","year":"2022","unstructured":"Heida, R., Hinrichs, W. L. J. & Frijlink, H. W. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19. Expert. Rev. Vaccines. 21, 957\u2013974 (2022).","journal-title":"Expert. Rev. Vaccines."},{"key":"1003_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.cell.2022.02.005","volume":"185","author":"S Afkhami","year":"2022","unstructured":"Afkhami, S. et al. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. Cell 185, 896\u2013915.e19 (2022).","journal-title":"Cell"},{"key":"1003_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17972-1","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu, S. et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 11, 4081 (2020).","journal-title":"Nat. Commun."},{"key":"1003_CR28","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/JLB.4MR0220-446R","volume":"108","author":"Z Xing","year":"2020","unstructured":"Xing, Z. et al. Innate immune memory of tissue-resident macrophages and trained innate immunity: Re-vamping vaccine concept and strategies. J. Leukoc. Biol. 108, 825\u2013834 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"1003_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18077-5","volume":"11","author":"L Feng","year":"2020","unstructured":"Feng, L. et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat. Commun. 11, 4207 (2020).","journal-title":"Nat. Commun."},{"key":"1003_CR30","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1473-3099(21)00396-0","volume":"21","author":"S Wu","year":"2021","unstructured":"Wu, S. et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect. Dis. 21, 1654\u20131664 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1003_CR31","doi-asserted-by":"publisher","first-page":"e239050","DOI":"10.1001\/jamanetworkopen.2023.9050","volume":"6","author":"R Mitchell","year":"2023","unstructured":"Mitchell, R. et al. Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022. Jama. Netw. Open. 6, e239050 (2023).","journal-title":"Jama. Netw. Open."},{"key":"1003_CR32","doi-asserted-by":"publisher","first-page":"e240288","DOI":"10.1001\/jamanetworkopen.2024.0288","volume":"7","author":"ST Anand","year":"2024","unstructured":"Anand, S. T. et al. Severe COVID-19 in Vaccinated Adults With Hematologic Cancers in the Veterans Health Administration. Jama. Netw. Open. 7, e240288 (2024).","journal-title":"Jama. Netw. Open."},{"key":"1003_CR33","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/j.eclinm.2022.101455","volume":"48","author":"V Auvigne","year":"2022","unstructured":"Auvigne, V. et al. Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021-January 2022: A retrospective, population-based, matched cohort study. EClinicalMedicine 48, 101455 (2022).","journal-title":"EClinicalMedicine"},{"key":"1003_CR34","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2023.2271","volume":"9","author":"WC Tan","year":"2023","unstructured":"Tan, W. C. et al. COVID-19 Severity and Waning Immunity After up to 4 mRNA Vaccine Doses in 73 608 Patients With Cancer and 621 475 Matched Controls in Singapore: A Nationwide Cohort Study. Jama. Oncol. 9, 1221\u20131229 (2023).","journal-title":"Jama. Oncol."},{"key":"1003_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abj5129","volume":"6","author":"JE Oh","year":"2021","unstructured":"Oh, J. E. et al. Intranasal priming induces local lung-resident B cell populations that secrete protective mucosal antiviral IgA. Sci. Immunol. 6, eabj5129 (2021).","journal-title":"Sci. Immunol."},{"key":"1003_CR36","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fmicb.2017.00900","volume":"8","author":"VMW Gould","year":"2017","unstructured":"Gould, V. M. W. et al. Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front. Microbiol. 8, 900 (2017).","journal-title":"Front. Microbiol."},{"key":"1003_CR37","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.immuni.2022.04.013","volume":"55","author":"RC Mettelman","year":"2022","unstructured":"Mettelman, R. C., Allen, E. K. & Thomas, P. G. Mucosal immune responses to infection and vaccination in the respiratory tract. Immunity 55, 749 (2022).","journal-title":"Immunity"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01003-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01003-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T05:07:16Z","timestamp":1730351236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01003-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1003"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01003-x","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.Z., J.G., R. W., S.A, H.H., X.Y.Z, L.W., M.Y., Y.L. and V.K.C. reported being employed by CanSino Biologics Inc. which manufacture the study vaccine, during the conduct of the study and outside the submitted work. J.G. and T.Z. reported holding stock in CanSino Biologics Inc. T.O.L. reported serving as a paid senior scientific advisor to CanSino Biologics Inc. S.Ng., D.N., S.B., R.Y., N.Z., S.S.C., A.A.A., C.C.K. and, L.H.P. reported receiving research grants via Clinical Research Malaysia (CRM) through a contract with CanSino Biologics Inc. during the conduct of the study and outside the submitted work. R.R. and X.W. received financial support from CanSino Biologics Inc. for contracted work outside the submitted work. X.X.X and J.S.T. received financial support from CanSino Biologics Inc. for contracted work outside the submitted work. G.Y.C., A.M.N, K.Y.C, Y.L.L, W.H.W.M, M.R.M.D., W.M.R.W.A.K. and M.H.T. reported receiving research grants from Clinical Research Malaysia (CRM) through a contract with CanSino Biologics Inc. No other disclosures were reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}